Description
According to the statistics, over 200 million people suffer from osteoporosis in the world. Among women aged 50 and above in China, 50% have low bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above.
Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs). Different from traditional estrogen replacement therapy (ERT) or hormone replacement therapy (HRT), raloxifene can not only prevent postmenopausal women from osteoporosis but also effectively increase bone mass and bone density so as to treat postmenopausal osteoporosis and prevent osteoporotic fracture.
View Full Report at: http://www.marketresearchreports.biz/analysis/294383
When raloxifene made by Eli Lilly under the trade name of Evista entered the market in 1997, its global sales value in the first year reached up to 285 million, making it the second most successful product of Eli Lilly. However, raloxifene’s annual sales value has been fluctuating around USD 1 billion after it reached its sales peak of USD 1.091 billion in 2007.
Raloxifene made by local enterprises came into the market after Evista entered China in Oct. 2003 and raloxifene’s CAGR was about 14% during the period of 2005-2014 according to CRI’s survey. Raloxifene enjoys a vast demand in China. Currently, raloxifene in the Chinese market are monopolized by the following three companies: Eli Lilly and Company (Spain), Eli Lilly and Company (UK) and Jiangsu Hengrui Medicine Co., Ltd, among which Eli Lilly and Company (Spain) has the largest market share of 86% for sales value in 2014.
Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/294383
Raloxifene market in China is expected to grow in the next few years.
Readers can get at least the following information from this report:
market size of raloxifene in China
competitive landscape of raloxifene in Chinese market
price of raloxifene made by different enterprises in China
market outlook of raloxifene in China
The author suggests the following groups of people purchase this report:
drug manufacturers
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E:
[email protected]